HealthcareServices

Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the solid tumor testing market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Solid Tumor Testing Market in 2030?

The solid tumor testing market has shown considerable expansion in recent years. It is anticipated to increase from $29.94 billion in 2025 to $32.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this market’s growth has been fueled by progress in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening programs.

The market for solid tumor testing is projected to experience robust expansion over the coming years. This market is anticipated to reach $43.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected period include the rising demand for personalized treatments, a greater emphasis on early detection, the broader application of genomic testing, the emergence of AI-driven diagnostics, and the expansion of oncology research. Key trends expected within the forecast timeframe encompass the proliferation of liquid biopsy testing, the uptake of next-generation sequencing, the wider availability of companion diagnostics, the incorporation of AI into pathology, and an increase in screening initiatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

What Drivers Are Influencing Production Trends In The Solid Tumor Testing Market?

The escalating incidence of cancer is anticipated to propel the expansion of the solid tumor testing market in the future. Cancer is a medical condition defined by the uncontrolled proliferation and spread of abnormal cells throughout the body. These aberrant cells, known as cancer cells, possess the ability to invade adjacent tissues and organs and, in certain instances, to disseminate to other parts of the body via the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are classified as solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients diagnosed with solid tumors, even before the cancer becomes visible on imaging scans. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males constituting about 55% of these diagnoses. Therefore, the rising prevalence of cancer is a primary driver for the growth of the solid tumor testing market.

Which Segment Groups Are Influencing The Solid Tumor Testing Market?

The solid tumor testing market covered in this report is segmented –

1) By Type: Genetic Testing, Conventional Testing

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

3) By Application: Clinical, Research

4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

Subsegments:

1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

Which Market Trends Are Opening Growth Opportunities In The Solid Tumor Testing Market?

Major companies engaged in the solid tumor testing market are prioritizing advancements, specifically liquid biopsy platforms for solid tumor analysis. A liquid biopsy platform utilizes diverse technologies and systems to examine bodily fluids, typically blood, for biomarkers associated with cancer. For example, in January 2023, PrognomiQ, a US-based healthcare firm, unveiled its multi-omics liquid biopsy platform. PrognomiQ has advanced its product development with the launch of a 15,000-subject prospective clinical program, which has already welcomed its first patient. This effort was motivated by the potential of multi-omics markers to differentiate between cancer cases and control groups.

Who Are The Top-Performing Companies In The Solid Tumor Testing Market In Recent Years?

Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Which Region Currently Holds The Largest Share Of The Solid Tumor Testing Market?

North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Solid Tumor Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

Hemato Oncology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Solid Tumor Cancer Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795